UNSPSC 51281615: Isepamicin

This classification denotes an aminoglycoside antibiotic with the molecular formula C22H43N5O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G7K224460P, chemically known as (s)-o-6-amino-6-deoxy-alpha-d-glucopyranosyl-(1.4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1.6))-1,3-diamino-n1-(3-aminolactoyl)-1,2,3-trideoxy-d-scyllo-inositol but generally known as isepamicin, which bears US NIH Compound Identifier 3755.

UNSPSC 51281615 Isepamicin (Commodity) shows minimal relevant activity in recent state and local procurement. The code nominally describes a specific aminoglycoside antibiotic, but the recent opportunities tagged under it diverge substantially from that scope — the posted solicitations cover naloxone and drug deactivation systems, direct-to-manufacturer pharmacy initiatives, fire department medical and first aid supplies, and generic multi-source pharmaceuticals and OTC products. None of these purchases represent isepamicin procurement or narrow pharmaceutical commodities aligned with the code's specific drug classification. State and local governments do purchase pharmaceuticals through cooperative agreements and direct institutional buys, but the current activity in this code does not reflect isepamicin demand.

The recent opportunities show issuing bodies across multiple sectors — a county health department (Seminole County, Florida), a state HHS commission (Texas), a municipal fire department (City of Tampa), and a multi-state cooperative purchasing alliance (MMCAP, administered through Minnesota with participating members including Oregon). The geographic spread includes Florida, Texas, Minnesota, and Oregon, with the cooperative model spanning multiple jurisdictions. Without misalignment between code and scope, representative solicitations would include Seminole County's IFB for naloxone systems (due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies (due March 13, 2026, estimated contract value $700,000), and MMCAP's RFP for generic pharmaceuticals and OTC products (due March 26, 2026). The code appears to be incorrectly applied to these opportunities and carries little signal for isepamicin-specific procurement activity.